These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 9607570)

  • 1. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
    Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
    Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
    Vujanovic NL; Yasumura S; Hirabayashi H; Lin WC; Watkins S; Herberman RB; Whiteside TL
    J Immunol; 1995 Jan; 154(1):281-9. PubMed ID: 7995947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
    Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL
    Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2.
    Nagashima S; Reichert TE; Kashii Y; Suminami Y; Chikamatsu K; Whiteside TL
    Cancer Gene Ther; 1997; 4(6):366-76. PubMed ID: 9408607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer.
    Whiteside TL; Chikamatsu K; Nagashima S; Okada K
    Anticancer Res; 1996; 16(4C):2357-64. PubMed ID: 8816835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of apoptosis in antibody-dependent cell-mediated cytotoxicity against monolayers of human squamous cell carcinoma of the head and neck targets.
    Sung MW; Nagashima S; Johnson JT; Van Dongen GA; Whiteside TL
    Cell Immunol; 1996 Jul; 171(1):20-9. PubMed ID: 8660833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
    Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
    Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
    Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes.
    Fox BA; Spiess PJ; Kasid A; Puri R; Mulé JJ; Weber JS; Rosenberg SA
    J Biol Response Mod; 1990 Oct; 9(5):499-511. PubMed ID: 2174966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor and antiangiogenic effects of interleukin 12 gene therapy in murine head and neck carcinoma model.
    Imagawa Y; Satake K; Kato Y; Tahara H; Tsukuda M
    Auris Nasus Larynx; 2004 Sep; 31(3):239-45. PubMed ID: 15364358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between autologous CD4+ and CD8+ T lymphocytes and human squamous cell carcinoma of the head and neck.
    Okada K; Yasumura S; Muller-Fleckenstein I; Fleckenstein B; Talib S; Koldovsky U; Whiteside TL
    Cell Immunol; 1997 Apr; 177(1):35-48. PubMed ID: 9140094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
    Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
    J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.
    Matsumura T; Sussman JJ; Krinock RA; Chang AE; Shu S
    Cancer Res; 1994 May; 54(10):2744-50. PubMed ID: 8168105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.